300702 天宇股份
已收盘 07-25 15:00:00
资讯
新帖
简况
天宇股份最新公告:上半年净利同比预增144%-238%
证券之星 · 07-15
天宇股份最新公告:上半年净利同比预增144%-238%
新冠药物概念盘中跳水,天宇股份跌0.27%
市场透视 · 07-15
新冠药物概念盘中跳水,天宇股份跌0.27%
天宇股份最新公告:全资子公司药品瑞舒伐他汀依折麦布片(I)获得批准
证券之星 · 07-10
天宇股份最新公告:全资子公司药品瑞舒伐他汀依折麦布片(I)获得批准
天宇股份(300702)股东林洁质押1050万股,占总股本3.02%
证券之星 · 07-08
天宇股份(300702)股东林洁质押1050万股,占总股本3.02%
高血压概念盘中跳水,天宇股份跌1.64%
市场透视 · 07-07
高血压概念盘中跳水,天宇股份跌1.64%
天宇股份遭实控人一致行动人近乎清仓式减持 预计套现金额超2亿元
新浪证券 · 06-27
天宇股份遭实控人一致行动人近乎清仓式减持 预计套现金额超2亿元
天宇股份最新公告:控股股东、实际控制人之一致行动人屠善增计划减持不超过3%公司股份
证券之星 · 06-25
天宇股份最新公告:控股股东、实际控制人之一致行动人屠善增计划减持不超过3%公司股份
高血压概念盘中跳水,天宇股份跌1.15%
市场透视 · 06-18
高血压概念盘中跳水,天宇股份跌1.15%
天宇股份最新公告:原料药厄贝沙坦获得CEP证书
证券之星 · 06-13
天宇股份最新公告:原料药厄贝沙坦获得CEP证书
天宇股份:公司CDMO业务板块的稳健发展依托原料药业务完善的GMP质量管理体系
证券之星 · 06-04
天宇股份:公司CDMO业务板块的稳健发展依托原料药业务完善的GMP质量管理体系
异动快报:天宇股份(300702)6月3日11点10分触及涨停板
证券之星 · 06-03
异动快报:天宇股份(300702)6月3日11点10分触及涨停板
天宇股份:5月13日召开业绩说明会,投资者参与
证券之星 · 05-13
天宇股份:5月13日召开业绩说明会,投资者参与
科兴制药与天宇股份达成战略合作
第一财经 · 05-01
科兴制药与天宇股份达成战略合作
每周股票复盘:天宇股份(300702)股东户数减少,业绩显著增长
证券之星 · 04-18
每周股票复盘:天宇股份(300702)股东户数减少,业绩显著增长
天宇股份(300702.SZ):2024年度净利润5593.51万元 拟10派0.5元
格隆汇 · 04-17
天宇股份(300702.SZ):2024年度净利润5593.51万元 拟10派0.5元
天宇股份(300702.SZ)全资子公司药品获得批准
智通财经 · 03-10
天宇股份(300702.SZ)全资子公司药品获得批准
天宇股份最新公告:全资子公司药品获得批准
证券之星 · 03-10
天宇股份最新公告:全资子公司药品获得批准
天宇股份收盘上涨3.02%,滚动市盈率149.38倍,总市值65.25亿元
金融界 · 03-07
天宇股份收盘上涨3.02%,滚动市盈率149.38倍,总市值65.25亿元
天宇股份最新公告:美国FDA关闭公司警告信
证券之星 · 03-03
天宇股份最新公告:美国FDA关闭公司警告信
天宇股份(300702.SZ):美国FDA关闭公司黄岩江口生产场地警告信
智通财经 · 03-03
天宇股份(300702.SZ):美国FDA关闭公司黄岩江口生产场地警告信
加载更多
公司概况
公司名称:
浙江天宇药业股份有限公司
所属行业:
医药制造业
上市日期:
2017-09-19
主营业务:
浙江天宇药业股份有限公司的主营业务是中间体、原料药以及制剂业务的研发、生产与销售。公司的主要产品是降血压类原料药及中间体、降血糖类原料药及中间体、抗凝血类原料药及中间体、制剂类、抗哮喘类原料药及中间体、降血脂类原料药及中间体。
发行价格:
22.41
{"stockData":{"symbol":"300702","market":"SZ","secType":"STK","nameCN":"天宇股份","latestPrice":24.94,"timestamp":1753427037000,"preClose":24.97,"halted":0,"volume":3557593,"delay":0,"changeRate":-0.0012,"floatShares":211000000,"shares":348000000,"eps":0.292,"marketStatus":"已收盘","change":-0.03,"latestTime":"07-25 15:00:00","open":24.91,"high":25.33,"low":24.74,"amount":89140300,"amplitude":0.0236,"askPrice":24.95,"askSize":9,"bidPrice":24.94,"bidSize":41,"shortable":0,"etf":0,"ttmEps":0.292,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":5,"adr":0,"adjPreClose":24.97,"symbolType":"stock","openAndCloseTimeList":[[1753407000000,1753414200000],[1753419600000,1753426800000]],"highLimit":27.47,"lowLimit":22.47,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":347977159,"isCdr":false,"pbRate":2.42,"roa":"--","peRate":85.410959,"roe":"2.43%","epsLYR":0.16,"committee":0.640954,"marketValue":8679000000,"turnoverRate":0.0168,"status":1,"floatMarketCap":5266000000},"requestUrl":"/m/hq/s/300702","defaultTab":"news","newsList":[{"id":"2551596150","title":"天宇股份最新公告:上半年净利同比预增144%-238%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551596150","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551596150?lang=zh_cn&edition=full","pubTime":"2025-07-15 17:00","pubTimestamp":1752570005,"startTime":"0","endTime":"0","summary":"天宇股份(300702.SZ)公告称,天宇股份发布2025年半年度业绩预告,预计归属于上市公司股东的净利润为1.3亿元–1.8亿元,比上年同期增长144.29%–238.25%。报告期内,公司积极把握市场机遇,拓宽客户渠道,优化产品结构,完善市场布局,加强成本管控,推动非沙坦类原料药及中间体、CDMO及制剂业务增长,同时减少外汇衍生品交易损失,实现业绩显著提升。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071500028435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2551373541","title":"新冠药物概念盘中跳水,天宇股份跌0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551373541","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551373541?lang=zh_cn&edition=full","pubTime":"2025-07-15 09:55","pubTimestamp":1752544521,"startTime":"0","endTime":"0","summary":"07月15日,新冠药物概念盘中跳水,截至09点55分,新冠药物概念整体指数下跌1.08%,报719.370点。从个股上来看,该概念的成分股中,天宇股份跌0.27%,星湖科技跌幅居前。从资金上来看,截止发稿,新冠药物概念主力净流入为-3.64亿,其中力生制药受到资金热捧,主力净流入3707.36万;拉长时间线来看,该板块近20日主力资金净流入-72.06亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507150955219542ceb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507150955219542ceb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0226","300702","BK0164","BK0239","BK0110","600866"],"gpt_icon":0},{"id":"2550628711","title":"天宇股份最新公告:全资子公司药品瑞舒伐他汀依折麦布片(I)获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2550628711","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550628711?lang=zh_cn&edition=full","pubTime":"2025-07-10 20:50","pubTimestamp":1752151828,"startTime":"0","endTime":"0","summary":"天宇股份(300702.SZ)公告称,公司全资子公司诺得药业收到国家药监局核准签发的关于瑞舒伐他汀依折麦布片(I)的《药品注册证书》。该药品适用于高胆固醇血症、纯合子型家族性高胆固醇血症(HoFH)。截至公告日,该制剂除诺得药业外,国内生产商另有北京福元医药股份有限公司。2024年该药品在国内样本医院和城市实体药店的销售额约481万元。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000036070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2550522557","title":"天宇股份(300702)股东林洁质押1050万股,占总股本3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550522557","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550522557?lang=zh_cn&edition=full","pubTime":"2025-07-09 00:21","pubTimestamp":1751991682,"startTime":"0","endTime":"0","summary":"证券之星消息,天宇股份7月9日公开信息显示,股东林洁向招商证券股份有限公司合计质押1050.0万股,占总股本3.02%。质押详情见下表:截止本公告日,股东林洁已累计质押股份2863.6万股,占其持股总数的23.47%,股东屠勇军已累计质押股份2450.0万股,占其持股总数的42.9%。天宇股份主营业务:化学原料药及中间体的研发、注册、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070900000520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2549473304","title":"高血压概念盘中跳水,天宇股份跌1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549473304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549473304?lang=zh_cn&edition=full","pubTime":"2025-07-07 13:14","pubTimestamp":1751865282,"startTime":"0","endTime":"0","summary":"07月07日,高血压概念盘中跳水,截至13点14分,高血压概念整体指数下跌1.01%,报1443.050点。从个股上来看,该概念的成分股中,天宇股份跌1.64%,普洛药业、恒瑞医药、立方制药跌幅居前。从资金上来看,截止发稿,高血压概念主力净流入为-1.26亿,其中福元医药受到资金热捧,主力净流入5666.79万;拉长时间线来看,该板块近20日主力资金净流入-9.17亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707131442a43b0b2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707131442a43b0b2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601089","300702","BK0239"],"gpt_icon":0},{"id":"2546579635","title":"天宇股份遭实控人一致行动人近乎清仓式减持 预计套现金额超2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546579635","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546579635?lang=zh_cn&edition=full","pubTime":"2025-06-27 14:15","pubTimestamp":1751004900,"startTime":"0","endTime":"0","summary":"近日,天宇股份发布公告称,公司控股股东、实际控制人之一致行动人屠善增拟减持不超过3%股份,减持金额或超2亿元。 以最近交易日收盘价计算,本次减持金额上限预计超过2.3亿元。 - 身份关键性:屠善增系公司实际控制人屠勇军的父亲,作为一致行动人,持股比例仅3.01%,此次减持后持股将降至0.01%,近乎清仓,信号意义强于普通股东; 本次减持虽合规,但实控人关联方近乎清仓的举动叠加融资困境,构成显著利空。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-06-27/doc-infcnwih6137084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2546483912","title":"天宇股份最新公告:控股股东、实际控制人之一致行动人屠善增计划减持不超过3%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2546483912","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546483912?lang=zh_cn&edition=full","pubTime":"2025-06-25 20:51","pubTimestamp":1750855863,"startTime":"0","endTime":"0","summary":"天宇股份(300702.SZ)公告称,公司收到控股股东、实际控制人之一致行动人屠善增的减持计划告知函,屠善增计划在2025年7月18日至10月15日期间,以集中竞价和大宗交易方式减持公司股份合计不超过10,439,314股,占公司总股本的3%。减持原因为股东自身资金需求,减持股份来源为公司首发上市前股份。减持价格将根据市场价格及相关规定确定。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062500036295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2544108189","title":"高血压概念盘中跳水,天宇股份跌1.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2544108189","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544108189?lang=zh_cn&edition=full","pubTime":"2025-06-18 09:48","pubTimestamp":1750211332,"startTime":"0","endTime":"0","summary":"06月18日,高血压概念盘中跳水,截至09点48分,高血压概念整体指数下跌1.12%,报1372.900点。从个股上来看,该概念的成分股中,天宇股份跌1.15%,一品红、可孚医疗、华海药业跌幅居前。从资金上来看,截止发稿,高血压概念主力净流入为-9383.05万,其中福元医药受到资金热捧,主力净流入763.61万;拉长时间线来看,该板块近20日主力资金净流入-16.79亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618094852a4af7f11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618094852a4af7f11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601089","BK0239","600521","300702"],"gpt_icon":0},{"id":"2543068137","title":"天宇股份最新公告:原料药厄贝沙坦获得CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2543068137","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543068137?lang=zh_cn&edition=full","pubTime":"2025-06-13 19:40","pubTimestamp":1749814834,"startTime":"0","endTime":"0","summary":"天宇股份(300702.SZ)公告称,公司收到欧洲药品质量管理局签发的关于厄贝沙坦(工艺II)原料药的欧洲药典适用性认证证书。同日公告,公司全资子公司诺得药业近日收到国家药监局核准签发的关于孟鲁司特钠片的《药品注册证书》。孟鲁司特钠片适用于15岁及15岁以上成人哮喘的预防和长期治疗。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061300035133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2540703748","title":"天宇股份:公司CDMO业务板块的稳健发展依托原料药业务完善的GMP质量管理体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2540703748","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540703748?lang=zh_cn&edition=full","pubTime":"2025-06-04 16:09","pubTimestamp":1749024549,"startTime":"0","endTime":"0","summary":"证券之星消息,天宇股份(300702)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,请问公司给创新药提供哪些产品?在创新药领域有哪些优势?天宇股份回复:感谢您的关注!公司主要业务涵盖中间体、原料药及制剂产品的研发、生产与销售,同时为创新制药企业提供专业的CDMO服务。公司CDMO业务板块的稳健发展,依托原料药业务完善的GMP质量管理体系及在原料药领域长期积累的专业经验,这使公司能够持续为客户创造价值,实现互利共赢。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060400022271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2540840745","title":"异动快报:天宇股份(300702)6月3日11点10分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2540840745","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540840745?lang=zh_cn&edition=full","pubTime":"2025-06-03 11:15","pubTimestamp":1748920522,"startTime":"0","endTime":"0","summary":"证券之星6月3日盘中消息,11点10分天宇股份触及涨停板。目前价格26.76,上涨18.04%。其所属行业化学制药目前上涨。领涨股为舒泰神。该股为新冠药物,化学原料药,医药概念热股,当日新冠药物概念上涨2.34%,化学原料药概念上涨2.21%,医药概念上涨1.66%。5月30日的资金流向数据方面,主力资金净流入695.91万元,占总成交额5.73%,游资资金净流入579.04万元,占总成交额4.77%,散户资金净流出1274.95万元,占总成交额10.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060300011576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2535266457","title":"天宇股份:5月13日召开业绩说明会,投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2535266457","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535266457?lang=zh_cn&edition=full","pubTime":"2025-05-13 19:07","pubTimestamp":1747134431,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年5月13日天宇股份发布公告称公司于2025年5月13日召开业绩说明会。公司 2025 年度 CDMO 业务收入 1.36 亿元,较上年同期下降约 4%,基本保持稳定态势。天宇股份主营业务:化学原料药及中间体的研发、注册、生产和销售。天宇股份2025年一季报显示,公司主营收入7.59亿元,同比上升10.13%;归母净利润8618.35万元,同比上升112.71%;扣非净利润8233.83万元,同比上升56.79%;负债率44.73%,投资收益-49.79万元,财务费用340.04万元,毛利率37.39%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051300031639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2532301735","title":"科兴制药与天宇股份达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2532301735","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532301735?lang=zh_cn&edition=full","pubTime":"2025-05-01 09:36","pubTimestamp":1746063402,"startTime":"0","endTime":"0","summary":"据科兴制药消息,科兴制药与浙江天宇药业股份有限公司签署战略合作协议,双方将围绕合作产品的海外商业化展开合作。近日,科兴制药与天宇股份旗下子公司浙江诺得药业有限公司达成磷酸西格列汀片在沙特、阿尔及利亚等国家的海外商业化独家合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050109372094e98790&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050109372094e98790&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["300702","BK0239","688136"],"gpt_icon":0},{"id":"2528014581","title":"每周股票复盘:天宇股份(300702)股东户数减少,业绩显著增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2528014581","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528014581?lang=zh_cn&edition=full","pubTime":"2025-04-19 05:00","pubTimestamp":1745010036,"startTime":"0","endTime":"0","summary":"截至2025年4月18日收盘,天宇股份报收于19.7元,较上周的18.05元上涨9.14%。本周,天宇股份4月18日盘中最高价报19.88元。本周关注点股本股东变化:截至2025年3月31日,天宇股份股东户数减少365户,减幅为2.44%业绩披露要点:天宇股份2024年年报显示,归母净利润同比增长104.45%股本股东变化近日天宇股份披露,截至2025年3月31日公司股东户数为1.46万户,较12月31日减少365.0户,减幅为2.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041900006874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2528746942","title":"天宇股份(300702.SZ):2024年度净利润5593.51万元 拟10派0.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528746942","media":"格隆汇","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528746942?lang=zh_cn&edition=full","pubTime":"2025-04-17 22:09","pubTimestamp":1744898966,"startTime":"0","endTime":"0","summary":"格隆汇4月17日丨天宇股份(300702.SZ)公布2024年年度报告,2024年公司实现营业收入26.31亿元,同比增长4.10%;归属于上市公司股东的净利润5593.51万元,同比增长104.45%;归属于上市公司股东的扣除非经常性损益的净利润6745.94万元,同比增长6.94;基本每股收益0.16元;拟向全体股东每10股派发现金红利0.5元(含税)。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/17220949636552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"天宇股份(300702.SZ):2024年度净利润5593.51万元 拟10派0.5元","news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300702"],"gpt_icon":0},{"id":"2518522683","title":"天宇股份(300702.SZ)全资子公司药品获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2518522683","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518522683?lang=zh_cn&edition=full","pubTime":"2025-03-10 20:40","pubTimestamp":1741610423,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份 公告,公司全资子公司浙江诺得药业有限公司于近日收到国家药品监督管理局核准签发的关于马来酸阿伐曲泊帕片、甲苯磺酸艾多沙班片的《药品注册证书》。据悉,马来酸阿伐曲泊帕片是血小板生成素受体激动剂,适用于择期行诊断性操作或者手术的慢性肝病相关血小板减少症的成年患者和既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2518715225","title":"天宇股份最新公告:全资子公司药品获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2518715225","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518715225?lang=zh_cn&edition=full","pubTime":"2025-03-10 20:29","pubTimestamp":1741609775,"startTime":"0","endTime":"0","summary":"天宇股份公告称,全资子公司诺得药业近日收到国家药监局核准签发的马来酸阿伐曲泊帕片、甲苯磺酸艾多沙班片的《药品注册证书》。甲苯磺酸艾多沙班片适用于非瓣膜性房颤患者预防卒中和体循环栓塞等,2023年国内销售额约3.61亿元。这些药品的获批将丰富公司制剂品种,有望增加公司制剂业务收入,对经营业绩产生积极影响。但药品未来生产、销售情况受市场环境影响,盈利水平存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000031086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2517101078","title":"天宇股份收盘上涨3.02%,滚动市盈率149.38倍,总市值65.25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517101078","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517101078?lang=zh_cn&edition=full","pubTime":"2025-03-07 17:41","pubTimestamp":1741340493,"startTime":"0","endTime":"0","summary":"3月7日,天宇股份今日收盘18.75元,上涨3.02%,滚动市盈率PE达到149.38倍,创102天以来新低,总市值65.25亿元。从行业市盈率排名来看,公司所处的化学制药行业市盈率平均46.07倍,行业中值26.20倍,天宇股份排名第132位。截至2024年三季报,共有3家机构持仓天宇股份,其中基金3家,合计持股数31.41万股,持股市值0.05亿元。最新一期业绩显示,2024年三季报,公司实现营业收入19.32亿元,同比3.61%;净利润8511.41万元,同比23.72%,销售毛利率35.47%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/07174148594959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2516689452","title":"天宇股份最新公告:美国FDA关闭公司警告信","url":"https://stock-news.laohu8.com/highlight/detail?id=2516689452","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516689452?lang=zh_cn&edition=full","pubTime":"2025-03-03 18:31","pubTimestamp":1740997865,"startTime":"0","endTime":"0","summary":"天宇股份公告称,公司于2022年8月26日披露了关于美国食品药品监督管理局对公司黄岩江口生产场地检查出具警告信的公告。根据评估结果,FDA认为公司已有效解决了该警告信中提及的偏差问题。本次FDA关闭公司黄岩江口生产场地警告信,将有利于公司产品市场的拓展,同时对公司新产品的获批将起到积极的作用,有助于提升公司的经营业绩。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030300027094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2516002686","title":"天宇股份(300702.SZ):美国FDA关闭公司黄岩江口生产场地警告信","url":"https://stock-news.laohu8.com/highlight/detail?id=2516002686","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516002686?lang=zh_cn&edition=full","pubTime":"2025-03-03 18:23","pubTimestamp":1740997382,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份(300702.SZ)公告,公司收到美国FDA关于关闭警告信的通知函,该通知函告知:FDA已完成对公司2022年8月17日签发的警告信(编号320-22-23)所采取纠正措施的评估。根据评估结果,FDA认为公司已有效解决了该警告信中提及的偏差问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300702"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753462524403,"stockEarnings":[{"period":"1week","weight":-0.0095},{"period":"1month","weight":0.0867},{"period":"3month","weight":0.1667},{"period":"6month","weight":0.4487},{"period":"1year","weight":0.5541},{"period":"ytd","weight":0.5}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0398},{"period":"3month","weight":0.0906},{"period":"6month","weight":0.1048},{"period":"1year","weight":0.2449},{"period":"ytd","weight":0.0722}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江天宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14617人(较上一季度减少2.44%)","perCapita":"14446股","listingDate":"2017-09-19","address":"浙江省台州市黄岩区黄岩江口化工开发区","registeredCapital":"34797万元","survey":" 浙江天宇药业股份有限公司的主营业务是中间体、原料药以及制剂业务的研发、生产与销售。公司的主要产品是降血压类原料药及中间体、降血糖类原料药及中间体、抗凝血类原料药及中间体、制剂类、抗哮喘类原料药及中间体、降血脂类原料药及中间体。","listedPrice":22.41},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天宇股份,300702,天宇股份股票,天宇股份股票老虎,天宇股份股票老虎国际,天宇股份行情,天宇股份股票行情,天宇股份股价,天宇股份股市,天宇股份股票价格,天宇股份股票交易,天宇股份股票购买,天宇股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}